How does faricimab compare to aflibercept for treating neovascular age-related macular degeneration?

✓ Accepted answer

Faricimab is a newer bi-specific antibody that targets both VEGF-A and Angiopoietin-2, whereas aflibercept is a fusion protein that blocks VEGF-A and VEGF-B.

• Reduced Injection Frequency: A key advantage of faricimab is its potential to reduce the number of annual intravitreal injections required for patients with neovascular AMD, which can improve convenience and adherence for seniors and their caregivers.
• Comparable Efficacy: Clinical research indicates that switching from aflibercept to faricimab maintains vision stability and provides non-inferior or superior outcomes, particularly for patients who previously had fluctuating responses to monotherapy VEGF-A inhibitors.
• Broader Mechanism of Action: By also inhibiting Angiopoietin-2, faricimab addresses additional pathways involved in vascular leakage and inflammation in the retina, which may help maintain the health of the retinal vasculature over time.
• Side Effect Profile: Both agents are administered via intravitreal injection, so common side effects remain similar, including transient increased intraocular pressure, pain at the injection site, and a small risk of endophthalmitis.
• Access and Cost: As faricimab is a newer agent, patients in the US and UK should verify insurance coverage or NHS funding availability, as cost-sharing structures may differ from the older, widely established aflibercept.

admin · 2026-10-13 19:37:13